The predictive value of glycated CD59 for fetal overgrowth in second-trimester pregnant women
- 1Department of Endocrinology, Suqian Hospital Affiliated to Xuzhou Medical University , ,
- 2Department of Endocrinology, Suqian Clinical College of Xuzhou Medical University , ,
Abstract
Objective: To investigate the predictive value of glycated CD59 (gCD59) during mid-pregnancy for adverse pregnancy outcomes, specifically macrosomia and large for gestational age (LGA), in a prospective cohort of pregnant women undergoing oral glucose tolerance testing (OGTT), with adjustment for gestational diabetes mellitus (GDM) status.
Methods: A total of 672 pregnant women who attended prenatal visits at the Affiliated Suqian Hospital of Xuzhou Medical University from January 2022 to July 2023 were enrolled, and baseline data were collected via the Zhendings Maternal and Child Health System. At 24–28 weeks of gestation, an oral glucose tolerance test (OGTT) was performed. Based on the results, participants were divided into a GDM group and a normal glucose tolerance (NGT) group for descriptive comparisons; for all predictive analyses, GDM status was included as a covariate in multivariable models. Concurrently, gCD59 levels were measured using the ELISA method. The pregnant women were followed up until after delivery, and data on delivery-related information and pregnancy outcomes were collected. Differences in pregnancy outcomes between the two groups were compared. Logistic regression analysis was used to identify risk factors for adverse pregnancy outcomes, and the predictive value of gCD59 levels for adverse pregnancy outcomes was assessed using ROC curves.
Results: Macrosomia and Large for Gestational Age (LGA) were the two most common adverse pregnancy outcomes. Compared with the NGT group, the incidence of macrosomia and LGA was significantly higher in the GDM group ( P < 0.05). Compared with the NGT group, gCD59 levels were significantly higher in the GDM group (1.49 (0.90, 2.33) vs. 0.87 (0.39, 1.62), P < 0.001). Logistic regression analysis indicated that gCD59 was an independent risk factor for macrosomia and LGA, and the incidence of macrosomia and LGA increased with rising gCD59 levels. In predictive modeling, the addition of gCD59 to traditional risk factors improved the AUC for macrosomia from 0.770 (95% CI: 0.679–0.833) to 0.864 (95% CI: 0.823–0.904) (DeLong P = 0.046); for LGA, the AUC improved from 0.723 (95% CI: 0.663–0.782) to 0.790 (95% CI: 0.737–0.843) (DeLong P = 0.103).
Conclusion: Macrosomia and LGA were the most common adverse pregnancy outcomes in the study cohort. gCD59 was identified as an independent risk factor for both macrosomia and LGA. In predictive modeling, gCD59 demonstrated statistically significant incremental value for macrosomia (AUC: 0.770 vs. 0.864, DeLong P = 0.046), while for LGA the improvement showed a favorable trend but did not reach statistical significance (AUC: 0.723 vs. 0.790, DeLong P = 0.103). These findings suggest that gCD59 may serve as a supplementary biomarker, particularly for risk stratification of macrosomia, with potential utility for identifying pregnancies at risk of excessive fetal growth.
Related
- A machine learning-based predictive model for gestational diabetes mellitus based on first trimester clinical indicators
- Changes in low back pain intensity following red ginger warm compresses among pregnant women in the third trimester: A pre-experimental study
- Prevalence and Hematological Profile of Anemia Among Third-Trimester Pregnant Women: A Retrospective Study From Al Adan Hospital, Kuwait.
- Restless legs syndrome among third-trimester pregnant women attending ANC Clinic in public hospitals in North Wollo Zone, Ethiopia
- First and second trimester concentrations of environmental phenols in association with gestational weight gain in the ECHO Cohort
BibTeX
@article{lu2026predictive,
title = {{The predictive value of glycated CD59 for fetal overgrowth in second-trimester pregnant women}},
author = {Xiaofan Lu and Hui Zhou and Qiang Gang and Mengmeng Dou and Ying Zhang and Yu Sun},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1924289},
url = {https://europepmc.org/article/PMC/PMC13668522},
note = {CC BY},
}
RIS
TY - JOUR
TI - The predictive value of glycated CD59 for fetal overgrowth in second-trimester pregnant women
AU - Xiaofan Lu
AU - Hui Zhou
AU - Qiang Gang
AU - Mengmeng Dou
AU - Ying Zhang
AU - Yu Sun
PY - 2026
DA - 2026/10/01
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1924289
UR - https://europepmc.org/article/PMC/PMC13668522
AB - Objective: To investigate the predictive value of glycated CD59 (gCD59) during mid-pregnancy for adverse pregnancy outcomes, specifically macrosomia and large for gestational age (LGA), in a prospective cohort of pregnant women undergoing oral glucose tolerance testing (OGTT), with adjustment for gestational diabetes mellitus (GDM) status. Methods: A total of 672 pregnant women who attended prenatal visits at the Affiliated Suqian Hospital of Xuzhou Medical University from January 2022 to July 2023 were enrolled, and baseline data were collected via the Zhendings Maternal and Child Health System. At 24–28 weeks of gestation, an oral glucose tolerance test (OGTT) was performed. Based on the results, participants were divided into a GDM group and a normal glucose tolerance (NGT) group for descriptive comparisons; for all predictive analyses, GDM status was included as a covariate in multivariable models. Concurrently, gCD59 levels were measured using the ELISA method. The pregnant women were followed up until after delivery, and data on delivery-related information and pregnancy outcomes were collected. Differences in pregnancy outcomes between the two groups were compared. Logistic regression analysis was used to identify risk factors for adverse pregnancy outcomes, and the predictive value of gCD59 levels for adverse pregnancy outcomes was assessed using ROC curves. Results: Macrosomia and Large for Gestational Age (LGA) were the two most common adverse pregnancy outcomes. Compared with the NGT group, the incidence of macrosomia and LGA was significantly higher in the GDM group ( P < 0.05). Compared with the NGT group, gCD59 levels were significantly higher in the GDM group (1.49 (0.90, 2.33) vs. 0.87 (0.39, 1.62), P < 0.001). Logistic regression analysis indicated that gCD59 was an independent risk factor for macrosomia and LGA, and the incidence of macrosomia and LGA increased with rising gCD59 levels. In predictive modeling, the addition of gCD59 to traditional risk factors improved the AUC for macrosomia from 0.770 (95% CI: 0.679–0.833) to 0.864 (95% CI: 0.823–0.904) (DeLong P = 0.046); for LGA, the AUC improved from 0.723 (95% CI: 0.663–0.782) to 0.790 (95% CI: 0.737–0.843) (DeLong P = 0.103). Conclusion: Macrosomia and LGA were the most common adverse pregnancy outcomes in the study cohort. gCD59 was identified as an independent risk factor for both macrosomia and LGA. In predictive modeling, gCD59 demonstrated statistically significant incremental value for macrosomia (AUC: 0.770 vs. 0.864, DeLong P = 0.046), while for LGA the improvement showed a favorable trend but did not reach statistical significance (AUC: 0.723 vs. 0.790, DeLong P = 0.103). These findings suggest that gCD59 may serve as a supplementary biomarker, particularly for risk stratification of macrosomia, with potential utility for identifying pregnancies at risk of excessive fetal growth.
SN - 1664-2392
ER -